NCT00198393 - Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

June 30, 2008

Study Completion Date

December 31, 2008

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Gefitinib

250 mg/day, until progression

DRUG

gemcitabine

1250 mg/m² D1 and D8 (D1=D28, until progression)

DRUG

Docetaxel

75 mg/m² D1 (D1=D22, until progression)

Trial Locations (2)

CHU Grenoble - pneumologie, Grenoble

CHU Avicenne - Oncologie, Bobigny